DENVER, CO – May 7, 2026 – Beacon Therapeutics, a leading innovator in genetic medicine, today announced promising 12-month data from its Phase II DAWN trial, showcasing sustained and significant improvements in visual function for patients suffering from X-linked retinitis pigmentosa (XLRP). The gene therapy candidate, laruparetigene zovaparvovec (laru-zova), demonstrated a favorable safety profile and continued positive effects on key visual measures, including low luminance visual acuity (LLVA) and macular sensitivity, reinforcing its potential as a transformative treatment for this debilitating inherited eye disease. These findings were presented at the prestigious Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting.
The DAWN trial (NCT06275620) investigated the efficacy and safety of laru-zova in patients with XLRP, a rare and progressive genetic disorder that leads to irreversible vision loss and eventual legal blindness. XLRP, caused by mutations in the retinitis pigmentosa GTPase regulator (RPGR) gene, currently lacks any approved therapeutic interventions. Beacon’s gene therapy aims to restore the natural function of photoreceptor cells, specifically rods and cones, by delivering a functional copy of the RPGRORF15 gene, enabling the production of the full-length protein essential for vision.
The 12-month follow-up data from the DAWN trial builds upon earlier nine-month findings, consistently demonstrating the therapeutic benefit of laru-zova. Patients treated with the gene therapy experienced sustained improvements in crucial visual markers, offering a beacon of hope for individuals affected by this condition. The therapy was generally well-tolerated, with no significant safety concerns reported over the observational period.
Sustained Visual Acuity and Macular Sensitivity Gains Highlight Therapeutic Efficacy
The Phase II DAWN trial results revealed compelling evidence of visual improvement. In patients receiving the high-dose regimen of laru-zova, a notable 50% achieved at least a two-line improvement (equivalent to 10 or more Early Treatment Diabetic Retinopathy Study – ETDRS letters) in visual acuity from their baseline measurements. Furthermore, an impressive 25% of high-dose recipients attained a three-line improvement (15 or more ETDRS letters), a significant achievement for individuals facing progressive vision loss. The low-dose arm of the study also showed encouraging results, with 67% of patients experiencing at least a two-line improvement in visual acuity.
Beyond visual acuity, the gene therapy also demonstrated sustained positive impacts on macular sensitivity, as measured by microperimetry. This critical measure assesses the sensitivity of the central retina, which is vital for detailed vision and reading. The data indicated a consistent improvement in mean macular sensitivity compared to baseline, suggesting that laru-zova not only halts vision loss but also actively restores some visual function in the macula.
Chronology of Development and Key Milestones
The journey of laruparetigene zovaparvovec from concept to clinical trials has been marked by strategic development and a commitment to addressing unmet medical needs in rare eye diseases.
- Gene Therapy Design: The development of laru-zova began with a deep understanding of the genetic underpinnings of XLRP, specifically focusing on the RPGR gene and its role in photoreceptor function. The gene therapy was engineered to deliver a functional copy of the RPGRORF15 gene, aiming to correct the underlying molecular defect.
- Pre-clinical Studies: Extensive pre-clinical research, including animal models of XLRP, provided the foundational evidence for the safety and potential efficacy of laru-zova, paving the way for human clinical trials.
- Phase I/II Clinical Trials: The initial phases of clinical development focused on evaluating the safety and tolerability of laru-zova and exploring preliminary efficacy signals. These early studies informed the design of subsequent larger trials.
- Phase II DAWN Trial: The DAWN trial (NCT06275620) was designed to further assess the efficacy and safety of laru-zova in a larger cohort of XLRP patients. The trial has provided crucial data, including the 12-month outcomes presented today, which have significantly strengthened the evidence base for the gene therapy.
- Enrollment in Pivotal VISTA Trial: Beacon Therapeutics has concurrently advanced its pivotal VISTA trial (NCT04850118), a critical step towards potential regulatory approval. Enrollment for the VISTA trial was completed in June 2025, with topline data anticipated in the second half of 2026. This trial is designed to provide the definitive evidence required for regulatory submissions.
- Initiation of LANDSCAPE Trial: Further expanding its clinical development program, Beacon has initiated dosing in the LANDSCAPE trial (NCT07174726). This study is specifically evaluating laru-zova in male participants aged 12 to 50 years diagnosed with XLRP at sites across the United States, broadening the patient population studied.
- ARVO 2026 Presentation: The recent presentation of the 12-month DAWN trial data at the ARVO Annual Meeting in Denver, Colorado (May 3-7, 2026), marks a significant milestone in communicating these promising clinical findings to the scientific and medical community.
Supporting Data and Statistical Significance
The statistical significance of the improvements observed in the DAWN trial underscores the therapeutic impact of laru-zova. The data presented at ARVO 2026 highlights:
- High Dose Efficacy:
- 50% of patients achieved ≥ 2-line improvement in visual acuity.
- 25% of patients achieved ≥ 3-line improvement in visual acuity.
- Low Dose Efficacy:
- 67% of patients achieved ≥ 2-line improvement in visual acuity.
- Sustained Macular Sensitivity: Consistent improvement in microperimetry mean sensitivity compared to baseline across treated patients.
- Safety Profile: Generally well-tolerated over 12 months, with no significant adverse events related to the gene therapy.
These quantitative results provide a robust foundation for the continued development of laru-zova. The ability to achieve such substantial improvements in visual function, particularly in a disease with no current treatment options, is highly encouraging. The dose-dependent nature of some outcomes also offers valuable insights for optimizing treatment strategies in future clinical applications.
Official Responses and Expert Opinions
The positive clinical outcomes have garnered enthusiastic responses from Beacon Therapeutics’ leadership and the wider ophthalmology community.
Dr. Daniel Chung, Chief Medical Officer of Beacon Therapeutics, expressed his optimism regarding the latest findings: "As we continue to build one of the most significant bodies of evidence for a gene therapy in ocular disease, these findings further support the ongoing clinical development of laru-zova and reinforce its potential as a meaningful treatment option for people living with XLRP." He emphasized that the sustained benefits observed over 12 months are particularly crucial for a progressive disease like XLRP, where long-term efficacy is paramount.
The presentation at the ARVO Annual Meeting provided a platform for peer review and discussion among leading researchers in the field of vision science. While specific quotes from external experts are not included in the provided text, the scientific rigor of the data and the significance of the findings are expected to generate considerable interest and positive discourse within the ophthalmology research community. The consistent results with previous nine-month data further solidify confidence in the therapy’s sustained impact.
Implications and Future Outlook
The implications of Beacon Therapeutics’ gene therapy for XLRP are far-reaching, offering a potential paradigm shift in the management of this devastating inherited retinal disease.
Addressing a Critical Unmet Need: XLRP currently represents a significant unmet medical need, leaving patients with no recourse as their vision deteriorates. The prospect of a therapeutic intervention that can restore or preserve vision is profoundly impactful, offering the potential to significantly improve the quality of life for affected individuals and their families.
Broadening Gene Therapy Applications: The success of laru-zova in XLRP could serve as a powerful precedent for the development of gene therapies for other inherited retinal diseases. The underlying principles of gene delivery and restoration of genetic function are broadly applicable, opening doors for future therapeutic advancements across a spectrum of genetic disorders.
Market Potential and Industry Trends: The global gene therapy market is experiencing rapid growth, driven by advancements in genetic engineering and a growing understanding of disease mechanisms. Reports from market intelligence firms, such as GlobalData (parent company of Clinical Trials Arena), predict a rise in the incidence of Retinitis Pigmentosa (RP) globally, from 1.04 million cases in 2024 to an estimated 1.08 million by 2029 across 16 major pharmaceutical markets. This increasing prevalence underscores the urgent need for effective treatments and highlights the substantial market opportunity for innovative therapies like laru-zova.
Regulatory Pathways and Patient Access: The successful completion of pivotal trials like VISTA will be crucial for Beacon Therapeutics to navigate the regulatory approval process. Positive data from these trials will pave the way for potential marketing authorization, ultimately aiming to make laru-zova accessible to patients who currently have limited or no treatment options.
Future Research and Development: The ongoing VISTA and LANDSCAPE trials represent the final critical stages of development for laru-zova. The anticipation surrounding the topline data from the VISTA trial in H2 2026 is palpable. Beacon’s commitment to further investigating the gene therapy in different trial settings and patient demographics demonstrates a comprehensive strategy to maximize its therapeutic potential and ensure its widespread availability.
In conclusion, Beacon Therapeutics’ latest data on laruparetigene zovaparvovec marks a significant stride forward in the fight against X-linked retinitis pigmentosa. The sustained visual improvements and favorable safety profile observed in the DAWN trial, coupled with the ongoing progress in pivotal studies, position this gene therapy as a highly promising candidate to revolutionize the treatment landscape for individuals living with this challenging condition. The coming months, particularly with the expected readout of the VISTA trial, will be critical in determining the future of this innovative therapy and its potential to restore sight for those affected by XLRP.
About the Author
